LM 305
Alternative Names: LM-305Latest Information Update: 01 Dec 2023
At a glance
- Originator LaNova Medicines Limited
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 15 Nov 2023 LaNova Medicines withdraws a phase I/II trial for Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) (IV), according to sponsor strategy (NCT05647512)
- 15 Nov 2023 LaNova Medicines withdraws a phase I/II trial for Multiple myeloma (Monotherapy, Second-line therapy or greater) (IV), according to sponsor strategy (NCT05647512)
- 12 May 2023 LM 305 LaNova Medicines licensed to AstraZeneca worldwide for the treatment of Multiple myeloma